Development and Application of an LC–MS Method for the Pharmacokinetics and Pharmacodynamics of Oral Therapeutic Efficacy of Nalfurafine
Basic & Clinical Pharmacology & Toxicology · 2026
DOI: 10.1111/bcpt.70178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Basic & Clinical Pharmacology & Toxicology, 2026. Verfasst von Sven Sondhauss und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand. Hauptthemen laut MEDLINE: Encephalomyelitis, Autoimmune, Experimental, Morphinans, Spiro Compounds, Multiple Sclerosis. Die Arbeit nennt 31 Literaturangaben. Gefördert von: Great New Zealand Trek, Ministry of Business, Innovation, and Employment, Neurological Foundation of New Zealand.
Abstract (Originalsprache)
Multiple sclerosis (MS) is a chronic autoimmune disease characterized by central nervous system demyelination, leading to sensory and motor dysfunction. Previous studies have demonstrated that the kappa opioid receptor agonist nalfurafine (Nalf) reduces disease severity and promotes remyelination in the experimental autoimmune encephalomyelitis (EAE) model of MS. However, the pharmacokinetics of Nalf and its optimal administration route for clinical translation remain unexplored. To investigate Nalf's pharmacokinetics and identify an effective oral delivery strategy, we successfully optimized a liquid chromatography–mass spectrometry (LC–MS) method for detecting Nalf in plasma and brain tissues of mice treated via intraperitoneal (ip) or oral administration. Nalf exhibited similar pharmacokinetic profiles following both ip and oral administration, with the oral route achieving almost 70% bioavailability and a longer elimination half‐life compared to ip. Nalf effectively reached the brain and significantly reduced a range of disease parameters in EAE in a dose‐dependent manner. Our findings demonstrate that oral administration of Nalf is pharmacokinetically favourable and effectively reduces disease disability and promotes remyelination in the EAE model. This study supports the clinical development of oral Nalf as a potential treatment for MS, offering an effective and noninvasive alternative to injections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand.
- Centre for Biodiscovery, Victoria University of Wellington, Wellington, New Zealand.
- Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia.
- Monash University, Clayton, Victoria, Australia.
- Department of Pharmaceutical Sciences, University of Kentucky, Lexington, Kentucky, USA.
- Department of Pathology and Molecular Medicine, University of Otago, Wellington, New Zealand.
ORCID-Profile: Sven Sondhauss, Katharina Robichon
Förderung
- Great New Zealand Trek
- Ministry of Business, Innovation, and Employment
- Neurological Foundation of New Zealand
- Health Research Council of New Zealand
Zitieren
APA
Sondhauss, S., Kiernan, M., Morizzi, J., Wright, P., Prisinzano, T. E., Kivell, B. M., Robichon, K., & La Flamme, A. C. (2026). Development and Application of an LC–MS Method for the Pharmacokinetics and Pharmacodynamics of Oral Therapeutic Efficacy of Nalfurafine. Basic & Clinical Pharmacology & Toxicology. https://doi.org/10.1111/bcpt.70178
Vancouver
Sondhauss S, Kiernan M, Morizzi J, Wright P, Prisinzano TE, Kivell BM, et al. Development and Application of an LC–MS Method for the Pharmacokinetics and Pharmacodynamics of Oral Therapeutic Efficacy of Nalfurafine. Basic & Clinical Pharmacology & Toxicology. 2026. doi:10.1111/bcpt.70178
BibTeX
@article{Sondhauss2026,
author = {Sondhauss, Sven and Kiernan, Mackenzie and Morizzi, Julia and Wright, Phil and Prisinzano, Thomas E and Kivell, Bronwyn M and Robichon, Katharina and La Flamme, Anne Camille},
title = {Development and Application of an LC–MS Method for the Pharmacokinetics and Pharmacodynamics of Oral Therapeutic Efficacy of Nalfurafine},
journal = {Basic & Clinical Pharmacology & Toxicology},
year = {2026},
doi = {10.1111/bcpt.70178}
}
EUVIMED